Clindamycin/tretinoin - Valeant Pharmaceuticals International

Drug Profile

Clindamycin/tretinoin - Valeant Pharmaceuticals International

Alternative Names: Acnatac; Acnex; CLin-RA; CLIN/RA Gel (1.2% clindamycin phosphate and crystalline 0.025% tretinoin aqueous gel) - Meda; Clindamycin/tretinoin gel - Meda; Tretinoin/clindamycin gel - Valeant Pharmaceuticals International; Ziana

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Developer Meda
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 24 Sep 2015 Launched for Acne vulgaris in Denmark (Topical)
  • 07 Apr 2014 Clindamycin/tretinoin licensed to Meda in Australia and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top